Rosanne Rouf, MD, Author at The Cardiology Advisor
Rosanne Rouf, MD

Rosanne Rouf, MD

Rosanne Rouf, MD, is director of the Heart Failure Program at Johns Hopkins Bayview Medical Center and an assistant professor in the School of Medicine. Her basic and translational research programs focus on the role of nonmyocyte pathobiology and sex differences in heart failure development in both injury-induced and genetic cardiomyopathies. To perform this work, she uses preclinical models to test pharmacologic and gene-targeted strategies to either prevent or reduce the onset of cardiovascular disease. Clinically, she is an advanced heart failure and transplant cardiologist and sees heart failure patients at Johns Hopkins Bayview. She is a dedicated clinician and clinical educator who actively participates in training medical students, residents and fellows in heart failure and basic/clinical research. Dr Rouf received her bachelor's and master's degrees in electrical engineering and computer science at Massachusetts Institute of Technology and her medical doctorate from Duke University School of Medicine. Following her internal medicine residency at Tufts Medical Center in Boston, she joined Johns Hopkins as an Adult Cardiology and Advanced Heart Failure/Transplant fellow and was a recipient of the prestigious American Heart Association Women in Cardiology Trainee Award in Excellence. After completing a fellowship, Dr Rouf joined the Johns Hopkins Advanced Heart Failure/Transplant faculty. She served as an attending physician on the inpatient Advanced Heart Failure/Transplant service at Johns Hopkins Hospital before being recruited to lead the heart failure program at Johns Hopkins Bayview Medical Center, located in Baltimore, Maryland.

All articles by Rosanne Rouf, MD

How I Treat My Patients With Sacubitril/Valsartan for Heart Failure With Reduced Ejection Fraction

Congestive heart failure (CHF) remains a leading cause of death and expenditure in the United States, affecting approximately 6.5 million people and costing more than $30 billion annually.1,2 Despite advances in medical therapy, the 5-year survival for patients with CHF is still approximately 50%.3 The prevalence of heart failure in the United States is expected…